Nicox S.A. (LON:0RCQ)

Market Cap	32.32M +90.8%
Revenue (ttm)	2.84M -63.4%
Net Income	-23.20M
EPS	-0.32
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,381
Average Volume	30,877
Open	0.4230
Previous Close	0.4200
Day's Range	0.4200 - 0.4230
52-Week Range	0.2000 - 0.6500
Beta	0.43
RSI	49.51
Earnings Date	Apr 21, 2026

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b cli...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RCQ

Financial Performance

In 2024, Nicox's revenue was 7.86 million, an increase of 13.84% compared to the previous year's 6.90 million. Losses were -22.39 million, 7.23% more than in 2023.

Financial numbers in EUR